MiniMed to announce financial results for its fourth quarter and full fiscal year 2026
Rhea-AI Summary
MiniMed (Nasdaq: MMED) will report fourth quarter and full fiscal year 2026 results on Wednesday, June 3, 2026. A news release will be issued at ~3:45 a.m. PDT and a webcast will follow at 5:45 a.m. PDT.
According to MiniMed, the fiscal year ends on April 24, 2026, and a replay and transcript will be posted within 24 hours at the company investor site.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – MMED
On the day this news was published, MMED gained 5.70%, reflecting a notable positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $234M to the company's valuation, bringing the market cap to $4.35B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peer stocks were flagged in the momentum scanner, so the slight 0.87% move appears stock-specific rather than part of a broader Healthcare/Health Information Services rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2026-03-18 | Product FDA clearance | Positive | -0.2% | FDA cleared MiniMed Flex™ insulin pump with strong real‑world Time in Range data. |
| 2026-03-09 | IPO completion | Positive | +1.8% | Closing of IPO with 28M shares at $20 and ~$538M in net proceeds. |
Recent major news showed a mixed pattern: one positive FDA clearance saw a slight negative reaction, while the IPO news aligned with a modest gain.
Over recent months, MiniMed has transitioned to trading as an independent public company and advanced its diabetes technology pipeline. The IPO on March 6, 2026 raised substantial capital, and FDA clearance for MiniMed Flex™ on March 18, 2026 accelerated commercialization plans. Today’s earnings-date announcement fits into this sequence as the first scheduled report covering these post-separation developments.
Market Pulse Summary
The stock moved +5.7% in the session following this news. A strong positive reaction aligns with anticipation around MiniMed’s first full reporting cycle as a standalone public company. The scheduled Q4 and FY 2026 release on June 3, 2026 follows recent milestones such as the IPO and MiniMed Flex™ clearance. Investors would need to weigh how much optimism had already been priced in and whether prior mixed reactions to good news signal potential for post-earnings volatility.
AI-generated analysis. Not financial advice.
MiniMed will host a webcast at 5:45 a.m. PDT on June 3, 2026, to discuss results for its fourth quarter and full fiscal year 2026. The webcast can be accessed at https://investors.minimed.com.
Within 24 hours of the webcast, a replay and transcript of the prepared remarks will be available by clicking on the Events link at https://investors.minimed.com.
About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in more than 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.
Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
View original content to download multimedia:https://www.prnewswire.com/news-releases/minimed-to-announce-financial-results-for-its-fourth-quarter-and-full-fiscal-year-2026-302740889.html
SOURCE MiniMed